Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.
Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.
复制标题
丁丙诺啡与丁丙诺啡/纳洛酮片剂对非依赖性阿片类药物滥用者的影响。
DOI：
10.1007/s002130050066
复制
发表时间：
2000
影响因子：
3.4
通讯作者：
Bigelow,GE
中科院分区：
文献类型：
--
作者：
Strain,EC;Stoller,K;Walsh,SL;Bigelow,GE
理由：丁丙诺啡是一种阿片类激动剂-拮抗剂，在美国正在开发，作为治疗阿片类药物依赖的舌下给药。丁丙诺啡可能被滥用;因此，已经开发了丁丙诺啡与纳洛酮组合的片剂，目的是降低身体依赖阿片类药物的人的滥用风险。尚未确定丁丙诺啡和丁丙诺啡/纳洛酮片剂在非依赖性阿片类药物滥用者中的特征和滥用潜力。阿片类药物（如丁丙诺啡）的非胃肠外滥用可能更可能发生在药物滥用障碍不太严重的人群中（例如，目的：评估舌下丁丙诺啡和丁丙诺啡/纳洛酮片剂在非依赖性阿片类药物滥用者中的滥用潜力。方法：在每周进行两次的实验室会话中，用舌下丁丙诺啡（4、8、16 mg）、舌下丁丙诺啡/纳洛酮（1/0.25、2/0.5、4/1、8/2、16/4 mg）以及肌内氢吗啡酮作为阿片类药物激动剂对照（2、4 mg）和安慰剂测试受试者（n=7）。结果：较高剂量的丁丙诺啡和丁丙诺啡/纳洛酮产生相似的阿片激动剂样作用。这些作用的发生减慢，与舌下给药途径一致，作用程度为中度。没有证据表明，除了纳洛酮衰减丁丙诺啡的阿片类激动剂的影响，在这个人口中，丁丙诺啡是由舌下route.Conclusions：这些结果表明，舌下丁丙诺啡和丁丙诺啡/纳洛酮可能都被滥用阿片类药物的用户谁是身体上依赖于阿片类药物。
Rationale:Buprenorphine is an opioid agonist-antagonist under development in the United States as a sublingual medication for treatment of opioid dependence. Buprenorphine may be abused; therefore, tablets combining buprenorphine with naloxone have been developed with the intent of reducing the abuse risk in people physically dependent upon opioids. The characteristics and abuse potential of buprenorphine and buprenorphine/naloxone tablets in non-dependent opioid abusers have not been determined. Non-parenteral abuse of opioids such as buprenorphine may be more likely in people who have less severe substance abuse disorders (e.g., are not physically dependent upon opioids).Objectives:To assess the abuse potential of sublingual buprenorphine and buprenorphine/naloxone tablets in non-dependent opioid abusers.Methods:Subjects (n=7) were tested with sublingual buprenorphine (4, 8, 16 mg), sublingual buprenorphine/naloxone (1/0.25, 2/0.5, 4/1, 8/2, 16/4 mg), as well as intramuscular hydromorphone as an opioid agonist control (2, 4 mg) and placebo in laboratory sessions conducted twice per week. Dosing was double-blind and double-dummy.Results:The higher doses of both buprenorphine and buprenorphine/naloxone produced similar opioid agonist-like effects. The onset of these effects was slowed, consistent with the sublingual route of administration, and the magnitude of effects was moderate. There was no evidence to suggest the addition of naloxone attenuated buprenorphine’s opioid agonist effects in this population when buprenorphine was delivered by the sublingual route.Conclusions:These results suggest that sublingual buprenorphine and buprenorphine/naloxone may both be abused by opioid users who are not physically dependent upon opioids.